miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic

Sun Lixin1, Sun Wei1, Song Haibin2

  • 1Department of General Surgery, Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

Molecular Carcinogenesis
|October 14, 2020
PubMed

Insights

MicroRNA-885-5p (miR-885-5p) is decreased in intrahepatic cholangiocarcinoma (iCCA), a cancer with rising incidence. Restoring miR-885-5p levels may inhibit iCCA progression and offer a new therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Intrahepatic cholangiocarcinoma (iCCA) incidence is rising globally, yet its molecular drivers are unclear.
  • MicroRNAs are increasingly recognized for their roles in cancer progression, including iCCA.

Purpose of the Study:

  • To investigate the role of miR-885-5p in the molecular pathogenesis of iCCA.
  • To identify potential therapeutic targets for iCCA based on microRNA regulation.

Main Methods:

  • Quantitative analysis of miR-885-5p expression in iCCA tissues.
  • In vitro and in vivo experiments using lentiviral vectors to manipulate miR-885-5p levels.
  • Mechanistic studies to identify direct and indirect targets of miR-885-5p.

Main Results:

  • miR-885-5p was significantly downregulated in iCCA tissues, correlating with poor survival outcomes.
  • Modulating miR-885-5p levels affected iCCA cell proliferation and metastasis.
  • miR-885-5p directly targets GALNT3 and indirectly downregulates IGF2BP1, inhibiting iCCA growth and metastasis.
  • miR-885-5p suppresses iCCA metastasis via the PI3K/AKT/MMPs pathway by targeting GALNT3.

Conclusions:

  • miR-885-5p acts as a tumor suppressor in iCCA by regulating GALNT3 and IGF2BP1.
  • miR-885-5p is a potential therapeutic target for intrahepatic cholangiocarcinoma treatment.

Related Concept Videos